Pharmacology
News
Doctors still overprescribing fluoroquinolones despite risks
“There probably is overprescription by primary care doctors for urinary tract infections and respiratory infections, when there could be...
Conference Coverage
Statins in NAFLD: Taking a closer look at benefits
Statins could have multiple benefits in NAFLD, but there has been little insight into how they may be exerting such effects.
News
Irritable bowel syndrome therapy removed from market (again)
Zelnorm, a short-term IBS-C treatment, has been removed from the market. The drug manufacturer cited “business concerns.”
News
FDA warning: Lymphoma drug heightens risk of death
FDA alert warns of increased risk of death and serious side affects with duvelisib, approved in 2018 to treat adults with CLL or SLL whose two...
News
No more ‘escape hatch’: Post Roe, new worries about meds linked to birth defects
Physicians fear that women won’t get the best treatments or will face dangerous risks.
News
Pemvidutide promising for fatty liver disease
Weight loss and multiple improvements in lipid parameters linked to nonalcoholic fatty liver disease were seen in a phase 1 trial.
News
Hydroxychloroquine risk found in some older patients with RA
Hydroxychloroquine initiation in older patients with rheumatoid arthritis and a history of heart failure was associated with an increased risk of...
News
Good chemo vs. bad chemo: When too much is a bad thing
Study questions the use of inpatient chemotherapy pointing to negative outcomes and high mortality among some patients.
Opinion
Adjuvant vs. neoadjuvant? What has ASCO 2022 taught us regarding resectable NSCLC?
Phase 3 trials are needed to determine whether neoadjuvant chemo/immunotherapy outperforms adjuvant chemo/immunotherapy.
News
$3 billion in cancer drug waste: Can it be salvaged?
Although most oncology drugs don’t incur substantial waste, even small volumes can translate to millions of dollars a year.